Abdallah Ahmed Elbakkoush1,
Anas Khaleel2,
Suleman Atique1,
Albakush Nura Ahmed Mohamed1,
Isatou Sowe1,
Chien-Tsai Liu1 
For correspondence:- Chien-Tsai Liu Email: ctliu@tmu.edu.tw
Received: 19 April 2016 Accepted: 5 March 2017 Published: 30 April 2017
Citation: Elbakkoush AA, Khaleel A, Atique S, Mohamed AN, Sowe I, Liu C. Enhancing contrast of magnetic resonance imaging in patients with liver cirrhosis: Conveyance times of Primovist in hepatobiliary system. Trop J Pharm Res 2017; 16(4):919-924 doi: 10.4314/tjpr.v16i4.25
© 2017 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To determine transit times for excretion of gadoxetic acid (Gd-EOB-DTPA), a recent magnetic resonance imaging (MRI) contrast agent, in hepatobiliary system of patients with liver cirrhosis.
Methods: Liver cirrhosis patients that underwent contrast MRI examination at Renai Hospital, Taipei City, Taiwan were included. The patients who have experienced contrast-enhanced abdominal MR examination after injection of 10 mL Gd-EOB-DTPA at 1.5-T MR from December 2009 to March 2011, were included retrospectively. The images were evaluated for the presence of contrast agent in intra-hepatic bile ducts (IHD), common bile duct (CBD), gall bladder and duodenum.
Results: The optimal time for arterial phase was from 15 s after injection while the optimal time for portal venous imaging was from 40 s after injection. Furthermore, the optimal time to observe changes was 20 min after contrast initiation of Gd-EOB-DTPA in 39 patients (83 %) in IHD and 37 patients (78.5 %) in CBD. Gall bladder reflux was visible in 26 patients (43 %), and duodenal excretion in 17 patients (36 %). After 30 min of contrast injection, Gd-EOB-DTPA could still be detected in 6 patients (13 %) in IHD and 7 patients (15 %) in CBD, while gall bladder reflux was visible in 10 patients (21 %), and duodenal excretion in 20 patients (55 %).
Conclusion: The excretion of Gd-EOB-DTPA can be observed in liver cirrhosis patients
Archives
News Updates
Fulltext in PDF